Clicky

Abbisko Cayman Ltd(2256)

Description: Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of ABSK091 and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations, as well as a licensing agreement with Sperogenix (Shanghai) MedTech Co., Ltd. to develop and commercialize ABSK021 for indications in non-oncology neurological rare diseases. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.


Keywords: Biotechnology Biopharmaceutical Life Sciences Cancer Immunotherapy Consultation Services Oncology Therapies Urothelial Cancer

Home Page: www.abbisko.com

Building 3
Shanghai,
China
Phone: 86 21 6891 2098


Officers

Name Title
Dr. Yao-Chang Xu Founder, Chairman & CEO
Dr. Hongping Yu Co-Founder, Sr. VP of Chemistry & Exec. Director
Dr. Zhui Chen Co-Founder, Sr. VP of Biology & Exec. Director
Dr. Zidong Zhang Chief Financial Officer
Ms. Huimin Tian Head of Operations & Joint Company Sec.
Mr. Yongyi Li Gen. Counsel
Ms. Jia Feng Head of Human Resource
Dr. Kewei Xie Chief Bus. Officer
Dr. Zhen Zhang VP and Head of Chemistry, Manufacturing & Controls
Dr. Jing Ji Chief Medical Officer

Exchange: HK

Country: HK : Hong Kong

Currency: Hong Kong Dollar (HK$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.8507
Price-to-Sales TTM: 97.8998
IPO Date:
Fiscal Year End: December
Full Time Employees: 192
Back to stocks